TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31183189

Group type: EXPERIMENTAL
Intervention: Confocal endoscopic microscopy (CEM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard endoscopic gastric mapping (white light endoscopy)
Number of subjects: 0
Study: 31183463

Group type: EXPERIMENTAL
Intervention: Enhanced recovery after surgery (ERAS) protocol
Number of subjects: 0
Study: 31183469

Group type: EXPERIMENTAL
Intervention: Sedation practices; 98.0% of respondents practiced sedation; primary indication for sedation was mechanical ventilation (94.0%).
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Drug choices for sedation; midazolam was the most preferred agent (90.0%).
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Delirium evaluation; nearly half of the participants routinely evaluated delirium using the confusion assessment method.
Number of subjects: 429
Study: 31183813

Group type: EXPERIMENTAL
Intervention: Eltrombopag (25, 50, 75, or 100 mg once daily)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Eltrombopag (continued treatment)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Eltrombopag (discontinued treatment)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Cytogenetic abnormalities
Number of subjects: 21
Study: 31183847

Group type: EXPERIMENTAL
Intervention: Subtherapeutic anticoagulation control (≤ 1 episode)
Number of subjects: 760

Group type: COMPARATOR
Intervention: No subtherapeutic anticoagulation control (control group)
Number of subjects: 760
Study: 31183877

Group type: EXPERIMENTAL
Intervention: Hu5F9-G4 (anti-CD47 monoclonal antibody)
Number of subjects: 19
Study: 31184558

Group type: EXPERIMENTAL
Intervention: Noninvasive fractional flow reserve (FFR) derived from coronary CT angiography
Number of subjects: 0

Group type: COMPARATOR
Intervention: Invasive fractional flow reserve (FFR)
Number of subjects: 0
Study: 31185256

Group type: EXPERIMENTAL
Intervention: Invasive ICP monitoring with a parenchymal probe (Camino) and tier-based management algorithm for elevated ICP
Number of subjects: 10
Study: 31185735

Group type: EXPERIMENTAL
Intervention: Antianginal medication escalation
Number of subjects: 901

Group type: EXPERIMENTAL
Intervention: Antianginal medication de-escalation
Number of subjects: 901

Group type: COMPARATOR
Intervention: No change in antianginal medications
Number of subjects: 901

Group type: EXPERIMENTAL
Intervention: Escalation correlates
Number of subjects: 901

Group type: EXPERIMENTAL
Intervention: De-escalation correlates
Number of subjects: 901

Group type: COMPARATOR
Intervention: Variation in escalation
Number of subjects: 901

Group type: COMPARATOR
Intervention: Variation in de-escalation
Number of subjects: 901
Study: 31185997

Group type: EXPERIMENTAL
Intervention: Integrated care services (home hospitalization, prehabilitation for major surgery, community-based interventions)
Number of subjects: 520000

Group type: EXPERIMENTAL
Intervention: Integrated care services
Number of subjects: 520000
Study: 31186258

Group type: EXPERIMENTAL
Intervention: Arthroscopic partial meniscectomy (APM)
Number of subjects: 641
Study: 31186274

Group type: EXPERIMENTAL
Intervention: Brentuximab-AVD (doxorubicin, vinblastine, dacarbazine)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Brentuximab-AVD
Number of subjects: 34
Study: 31186669

Group type: EXPERIMENTAL
Intervention: IQP-AO-101
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 31187233

Group type: EXPERIMENTAL
Intervention: gFTRD (Ovesco Endoscopy, Tübingen, Germany)
Number of subjects: 29
Study: 31187454

Group type: EXPERIMENTAL
Intervention: Intrathecal VTS-270 at doses of 50, 200, 300, or 400 mg per month, escalated to 600 or 1200 mg as tolerated.
Number of subjects: 14
Study: 31188201

Group type: EXPERIMENTAL
Intervention: CFS 5 (frail)
Number of subjects: 937

Group type: EXPERIMENTAL
Intervention: CFS 6/7 (severely frail)
Number of subjects: 937

Group type: EXPERIMENTAL
Intervention: Frailty presence (CFS 5-7)
Number of subjects: 937

Group type: COMPARATOR
Intervention: Overall population
Number of subjects: 937

Group type: EXPERIMENTAL
Intervention: Increasing frailty
Number of subjects: 937

Group type: EXPERIMENTAL
Intervention: CFS 5-7 (frail)
Number of subjects: 937
Study: 31188267

Group type: EXPERIMENTAL
Intervention: BPS
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: NCS-I
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: NCS-R-I
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Videopupillometry
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: BPS, NCS-I, NCS-R-I
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: NCS-I, NCS-R-I
Number of subjects: 50
Study: 31188726

Group type: EXPERIMENTAL
Intervention: Carfilzomib
Number of subjects: 95

Group type: COMPARATOR
Intervention: Bortezomib
Number of subjects: 95
Study: 31189036

Group type: EXPERIMENTAL
Intervention: Metagenomic NGS of CSF
Number of subjects: 204

Group type: COMPARATOR
Intervention: Routine microbiologic testing
Number of subjects: 204
Study: 31189377

Group type: EXPERIMENTAL
Intervention: Health literacy intervention consisting of three workshops
Number of subjects: 407
Study: 31189673

Group type: EXPERIMENTAL
Intervention: HPV presence and viral load measured via qPCR
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Local concentrations of cytokines measured via MesoScale Discovery technology
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Immune cells measured via flow cytometry
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Vaginal microbiota sequencing (16S and ITS1 loci)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Titration of circulating anti-HPV antibodies
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Weekly self-samples for HPV monitoring
Number of subjects: 150
Study: 31189731

Group type: EXPERIMENTAL
Intervention: Needle aspiration (NA) performed ≥48 hours after symptom onset
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Needle aspiration (NA) performed <48 hours after symptom onset
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Needle aspiration (NA) in prospective cohort
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Needle aspiration (NA) performed after 48 hours of symptoms' onset in prospective cohort
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Needle aspiration (NA) performed <48 hours after symptoms' onset in prospective cohort
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Delay between first symptom and NA procedure ≥48 hours
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Smaller pneumothorax estimated by Light's index
Number of subjects: 217
Study: 31190006

Group type: EXPERIMENTAL
Intervention: Bendamustine 225 mg/m²
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-dose melphalan (MEL200)
Number of subjects: 0
Study: 31190179

Group type: EXPERIMENTAL
Intervention: Leaders being positive and engaged in the intervention, holding clear goals and visions for the intervention in the clinic.
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Understanding of outcome monitoring as a resource for practice improvement.
Number of subjects: 26
Study: 31190276

Group type: EXPERIMENTAL
Intervention: Eribulin 1.4 mg/m² combined with carboplatin (AUC 5 or 6 mg/mL·min)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eribulin 1.1 mg/m² combined with carboplatin (AUC 5 or 6 mg/mL·min)
Number of subjects: 0
Study: 31190298

Group type: EXPERIMENTAL
Intervention: Intravenous fosfomycin (IV) administered at an average daily dose of 13.7±3.5 g over 12.4±8.6 days, almost exclusively in combination with other antibiotics.
Number of subjects: 209
Study: 31190584

Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation
Number of subjects: 0
Study: 31191000

Group type: EXPERIMENTAL
Intervention: Colon Inflammatory Index (CII) based on neutrophil-to-lymphocyte ratio and lactate dehydrogenase
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 31191007

Group type: EXPERIMENTAL
Intervention: Simotinib, a novel specific EGFR tyrosine kinase inhibitor, dosage and duration not specified.
Number of subjects: 0
Study: 31191190

Group type: EXPERIMENTAL
Intervention: Plant-based diet (PBD)
Number of subjects: 36
Study: 31191235

Group type: EXPERIMENTAL
Intervention: High-definition transcranial direct current stimulation (HD-tDCS) - 20 daily sessions, 1 mA, 20 min, 4 mm ring radius.
Number of subjects: 1

Group type: COMPARATOR
Intervention: Baseline measurements prior to intervention.
Number of subjects: 1
Study: 31191688

Group type: EXPERIMENTAL
Intervention: Cells from the acetabulum
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Cells from the bone marrow
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Cells from the femur
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Bone marrow cells
Number of subjects: 3
Study: 31191908

Group type: EXPERIMENTAL
Intervention: Active knowledge translation intervention including the addition of the Kidney Failure Risk Equation (KFRE) and decision aids to clinics' Data Presentation Tool (DPT), patient-facing visual aids, a medical detailing visit, and sentinel feedback reports.
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group exposed only to current guidelines for CKD management, without active dissemination.
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Surveys administered in the clinic post-visit to measure CKD-specific health literacy and trust in physician care.
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: At the provider level, measuring satisfaction with the risk prediction tools.
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: At the health system level, assessing cost of CKD care and appropriate referrals for patients at high risk of kidney failure based on provincial guidelines.
Number of subjects: 32
Study: 31191965

Group type: EXPERIMENTAL
Intervention: Symptomatic players with long-standing groin pain
Number of subjects: 102

Group type: COMPARATOR
Intervention: Controls (age-matched, asymptomatic)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Symptomatic players with groin pain
Number of subjects: 102
Study: 31191990

Group type: EXPERIMENTAL
Intervention: ILM peeling with inverted flap technique
Number of subjects: 7
Study: 31192894

Group type: EXPERIMENTAL
Intervention: Daily Oral TDF/FTC PrEP
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 31192910

Group type: EXPERIMENTAL
Intervention: Risk stratification protocols and clinical, physical, and biochemical parameters
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Clinical, physical, and biochemical parameters measured before and after CRP
Number of subjects: 44
Study: 31192960

Group type: EXPERIMENTAL
Intervention: BCQ assessment and glycoproteomics approach
Number of subjects: 6

Group type: COMPARATOR
Intervention: BCQ assessment
Number of subjects: 6
Study: 31193095

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention aimed at weight reduction
Number of subjects: 15269

Group type: COMPARATOR
Intervention: Medical nutrition therapy
Number of subjects: 15269

Group type: COMPARATOR
Intervention: Mail/telephone outreach
Number of subjects: 15269

Group type: COMPARATOR
Intervention: Media/advertising
Number of subjects: 15269
Study: 31193254

Group type: EXPERIMENTAL
Intervention: Herpes zoster (HZ) incidence
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Postherpetic neuralgia (PHN) incidence
Number of subjects: 391
Study: 31193334

Group type: EXPERIMENTAL
Intervention: Amyloid-positive patients
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: ε4 homozygous or amyloid-positive patients
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: ε4 homozygous, family history-positive, or amyloid-positive patients
Number of subjects: 148

Group type: COMPARATOR
Intervention: Unenriched patients
Number of subjects: 148
Study: 31193477

Group type: EXPERIMENTAL
Intervention: AV2
Number of subjects: 327

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 327
Study: 31193580

Group type: COMPARATOR
Intervention: Centralized vaccine reminder/recall (R/R) via autodialed telephone and mail, up to 3 reminders.
Number of subjects: 15769

Group type: EXPERIMENTAL
Intervention: Usual care (control group).
Number of subjects: 15769
Study: 31193613

Group type: EXPERIMENTAL
Intervention: Standard prophylactic intravenous hydration
Number of subjects: 660

Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 660
Study: 31193620

Group type: EXPERIMENTAL
Intervention: Single dose mebendazole
Number of subjects: 185

Group type: COMPARATOR
Intervention: Multiple dose mebendazole
Number of subjects: 185
Study: 31193636

Group type: EXPERIMENTAL
Intervention: Smartphone-based event recorder (AliveCor) alongside standard care
Number of subjects: 243

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 243
Study: 31193674

Group type: EXPERIMENTAL
Intervention: 1 g dose of multi-OIT
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 300 mg dose of multi-OIT
Number of subjects: 70

Group type: COMPARATOR
Intervention: 0 mg dose (discontinuation of multi-OIT)
Number of subjects: 70
Study: 31193824

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 231

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 231
Study: 31193919

Group type: EXPERIMENTAL
Intervention: Hospital discharge smoking cessation intervention
Number of subjects: 942

Group type: COMPARATOR
Intervention: Tobacco use during hospitalization
Number of subjects: 942
Study: 31194225

Group type: EXPERIMENTAL
Intervention: Niraparib 200 mg orally once daily plus Pembrolizumab 200 mg intravenously on day 1 of each 21-day cycle
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Niraparib plus Pembrolizumab
Number of subjects: 55
Study: 31194228

Group type: EXPERIMENTAL
Intervention: Niraparib 200 mg orally once daily and Pembrolizumab 200 mg intravenously on day 1 of each 21-day cycle
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Niraparib in combination with Pembrolizumab
Number of subjects: 62
Study: 31194247

Group type: EXPERIMENTAL
Intervention: Afatinib (40 mg/d)
Number of subjects: 617

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 617

Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 617
Study: 31194611

Group type: EXPERIMENTAL
Intervention: Nivolumab in cohort A (untreated brain metastases)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Nivolumab in cohort B (prior therapy)
Number of subjects: 73
Study: 31194748

Group type: EXPERIMENTAL
Intervention: Cystic fibrosis (CF) patients
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Non-cystic fibrosis (non-CF) patients
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: CT score
Number of subjects: 102
Study: 31194764

Group type: EXPERIMENTAL
Intervention: Exercise (PEX)
Number of subjects: 932

Group type: EXPERIMENTAL
Intervention: Exercise plus testosterone (TEX)
Number of subjects: 932

Group type: COMPARATOR
Intervention: HDBR alone (CON)
Number of subjects: 932
Study: 31194872

Group type: EXPERIMENTAL
Intervention: Metreleptin (0.08 to 0.16 mg/kg) for 12 months
Number of subjects: 29
Study: 31194884

Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine system (LNG-IUS)
Number of subjects: 1100
Study: 31194939

Group type: EXPERIMENTAL
Intervention: Daily food choices
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Monotonous diet (meal replacement beverages)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Overall dietary diversity
Number of subjects: 34
Study: 31195062

Group type: EXPERIMENTAL
Intervention: Sofosbuvir/velpatasvir (400 mg/100 mg) once daily for 12 weeks
Number of subjects: 59
Study: 31195984

Group type: EXPERIMENTAL
Intervention: Visceral adipose tissue (VAT) measurement
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: VAT/SMT ratio measurement
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Prognostic scores (APACHE-II, Ranson's, BISAP, SIRS)
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: VAT measurement
Number of subjects: 306
Study: 31195991

Group type: EXPERIMENTAL
Intervention: Detection of aberrant methylation of ctDNA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Detection of mutations in ctDNA
Number of subjects: 0
Study: 31195996

Group type: EXPERIMENTAL
Intervention: Eribulin mesylate 1.4 mg/m²
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Eribulin mesylate 1.4 mg/m² + Trastuzumab
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 108
Study: 31196083

Group type: EXPERIMENTAL
Intervention: Self-report questionnaires assessing medication adherence (CQR)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Beliefs about Medicines Questionnaire (BMQ)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Satisfaction with Information about Medicines Scale (SIMS)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Multiple logistic regression analysis
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: EuroQol five-dimensions (EQ5D)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Systemic Lupus International Collaborating Clinics (SLICC)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Use of NSAID
Number of subjects: 210
Study: 31196179

Group type: EXPERIMENTAL
Intervention: Synovial fluid biomarkers (sVCAM-1 and MMP-3)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Six OA-related SF biomarkers
Number of subjects: 25
Study: 31196203

Group type: EXPERIMENTAL
Intervention: High-resolution manometry (HRM) catheter
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional balloon catheter
Number of subjects: 20
Study: 31196680

Group type: EXPERIMENTAL
Intervention: Pazopanib
Number of subjects: 706
Study: 31196892

Group type: EXPERIMENTAL
Intervention: Sulfonylurea therapy
Number of subjects: 0
Study: 31196903

Group type: EXPERIMENTAL
Intervention: Assessment of anthropometrical measures, puberty development, nutritional biomarkers, symptoms of depression, anxiety, and trauma using validated scales.
Number of subjects: 1425
Study: 31197640

Group type: EXPERIMENTAL
Intervention: Log-logistic model applied in clinical trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Best dropout model (log-logistic) incorporated in the final two-state model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical trial simulation
Number of subjects: 0
Study: 31197699

Group type: EXPERIMENTAL
Intervention: Surgical intervention (distal pancreatectomy, Whipple, total pancreatectomy)
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Surgical intervention
Number of subjects: 354
Study: 31198061

Group type: EXPERIMENTAL
Intervention: Continuous electroencephalography (EEG) monitoring
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Continuous electroencephalography background features
Number of subjects: 152
Study: 31198489

Group type: EXPERIMENTAL
Intervention: Hormonal skin diagnostic testing with intradermal injections of Progesterone, Estradiol, Estrone, and Estriol; followed by serial desensitization injections
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo solvent injections
Number of subjects: 35
Study: 31198551

Group type: EXPERIMENTAL
Intervention: Triceps lifting approach
Number of subjects: 43

Group type: COMPARATOR
Intervention: Olecranon osteotomy
Number of subjects: 43
Study: 31198606

Group type: EXPERIMENTAL
Intervention: PPV with ILM peeling
Number of subjects: 22
Study: 31198661

Group type: EXPERIMENTAL
Intervention: Direct mailing of fecal screening tests
Number of subjects: 18226

Group type: COMPARATOR
Intervention: Control group not explicitly mentioned
Number of subjects: 18226
Study: 31198947

Group type: EXPERIMENTAL
Intervention: Maternal aflatoxin exposure (measured via AFB1-lysine adduct concentration)
Number of subjects: 1621

Group type: EXPERIMENTAL
Intervention: Maternal aflatoxin exposure
Number of subjects: 1621
Study: 31199305

Group type: EXPERIMENTAL
Intervention: HITSystem 2.0
Number of subjects: 108
Study: 31199324

Group type: EXPERIMENTAL
Intervention: CliniPup (serious game for health)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 20
Study: 31199326

Group type: EXPERIMENTAL
Intervention: Home-care intervention (electronic PrEP, ePrEP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care (control)
Number of subjects: 0
Study: 31199334

Group type: EXPERIMENTAL
Intervention: eCDSS (electronic clinical decision support system) integrated into primary care workflows.
Number of subjects: 995

Group type: EXPERIMENTAL
Intervention: eCDSS (electronic clinical decision support system)
Number of subjects: 995
Study: 31199335

Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy (NRT) provided for up to 3 months upon request, along with continuous smoking cessation (SC) counseling and behavioral support.
Number of subjects: 1184

Group type: EXPERIMENTAL
Intervention: Continuous smoking abstinence (SA) verified at each visit using self-reporting and chemical verification.
Number of subjects: 1184

Group type: EXPERIMENTAL
Intervention: Biomarkers of effect assessed in urine and blood at baseline, Month 3, Month 6, and Month 12.
Number of subjects: 1184

Group type: EXPERIMENTAL
Intervention: Safety assessments included adverse events and serious adverse events, body weight, vital signs, spirometry, electrocardiogram, clinical chemistry, hematology and urine analysis safety panel, physical examination, and concomitant medications.
Number of subjects: 1184
Study: 31199341

Group type: EXPERIMENTAL
Intervention: Adjunct treatment components tailored for YMSM including assertive communication training videos and motivational interviewing focused on assisting with identification and development (MI-AID) before CHTC.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Most successful adapted intervention package from Phase 2.
Number of subjects: 24
Study: 31199347

Group type: EXPERIMENTAL
Intervention: Arousal feedback-based exposure therapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 50
Study: 31199799

Group type: EXPERIMENTAL
Intervention: Hair cortisol levels in sarcoidosis patients
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Hair testosterone levels in sarcoidosis patients
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Correlation of hair cortisol with anxiety
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Correlation of hair cortisol with depression
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Correlation of hair cortisol with SF-36 mental domain
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Correlation of hair cortisol with fatigue
Number of subjects: 32
Study: 31199858

Group type: EXPERIMENTAL
Intervention: Preoperative cerebral microbleeds (CMB) detected via MRI
Number of subjects: 65